因嵌合抗原受体T细胞相关毒性入住ICU患者的特点与结局:法国多中心队列研究
该回顾性观察队列纳入2018-2022年法国两家ICU连续收治的CAR-T治疗后3个月内成人患者。238例接受CAR-T治疗者中84例(35.3%)入ICU,中位入ICU时间为输注后5[0-7]天。细胞因子释放综合征(CRS)占95.2%,其中22.5%为3-4级;免疫效应细胞相关神经毒性综合征(ICANS)占54.8%,其中63%为3-4级。ICU死亡率4.8%,一年时48.9%存活并完全缓解,结局与未入ICU患者相似。
要点
- 238例CAR-T治疗患者中84例(35.3%)入ICU,中位入ICU时间5[0-7]天,SOFA中位3[2-6]分、SAPSII中位39[30-48]分。
- CRS 80/84(95.2%),其中18/80(22.5%)为3-4级;ICANS 46/84(54.8%),其中29/46(63%)为3-4级。
- 托珠单抗用于73/84(86.9%),中位2[1-4]剂;激素用于55/84(65.5%),其中21/55(38.2%)接受大剂量冲击治疗。
- 需血管活性药23/84(27.4%)、有创机械通气12/84(14.3%)、透析4/84(4.8%);细菌感染23/84(27.4%)、真菌感染3/84(3.6%)。
- ICU死亡4例(其中2例为再入ICU后死亡),总体死亡率4.8%;一年时48.9%存活并完全缓解、16.7%存活但复发、34.5%死亡。
适用人群与场景
- 2018-2022年法国两家ICU连续收治的CAR-T治疗后3个月内成人患者,共84例。
诊断标准与关键阈值
- 细胞因子释放综合征诊断标准在80/84(95.2%)患者中满足,其中18/80(22.5%)为3-4级毒性。
- 免疫效应细胞相关神经毒性综合征(ICANS)发生在46/84(54.8%)患者中,其中29/46(63%)为3-4级毒性。
- 噬血细胞性淋巴组织细胞增多症在15/84(17.9%)患者中诊断。
处置流程与药物剂量
- 托珠单抗用于73/84(86.9%)患者,中位2[1-4]剂。
- 激素用于55/84(65.5%)患者,其中21/55(38.2%)接受大剂量冲击治疗。
- 血管活性药用于23/84(27.4%)患者。
- 有创机械通气用于12/84(14.3%)患者。
- 透析用于4/84(4.8%)患者。
研究设计与关键结果
- 回顾性观察队列研究,纳入法国两家ICU的84例CAR-T治疗后3个月内成人患者,中位入ICU时间为输注后5[0-7]天。
- 中位SOFA评分3[2-6]分,中位SAPSII评分39[30-48]分。
- CRS 80/84(95.2%),3-4级18/80(22.5%);ICANS 46/84(54.8%),3-4级29/46(63%);噬血细胞性淋巴组织细胞增多症15/84(17.9%)。
- 细菌感染23/84(27.4%),真菌感染3/84(3.6%)(1例侵袭性肺曲霉病和2例毛霉目),巨细胞病毒感染2/84(2.4%)。
- ICU死亡4例(包括2例再入ICU后死亡),总体死亡率4.8%;一年时存活并完全缓解41/84(48.9%),存活但复发14/84(16.7%),死亡29/84(34.5%),结局与未入ICU患者相似。
证据类型、等级与局限
- 证据类型:回顾性观察队列研究(法国两家ICU)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,尽管3-4级毒性发生率高,但ICU死亡率低,且一半患者一年时存活并完全缓解,这一经验令人鼓舞。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) therapy is increasingly used in patients with refractory haematological malignancies but can induce severe adverse events. We aimed to describe the clinical features and outcomes of patients admitted to the intensive care unit (ICU) after CAR-T therapy.
METHODS: This retrospective observational cohort study included consecutive adults admitted to either of two French ICUs in 2018-2022 within 3 months after CAR-T therapy.
RESULTS: Among 238 patients given CAR-T therapy, 84 (35.3%) required ICU admission and were included in the study, a median of 5 [0-7] days after CAR-T infusion. Median SOFA and SAPSII scores were 3 [2-6] and 39 [30-48], respectively. Criteria for cytokine release syndrome were met in 80/84 (95.2%) patients, including 18/80 (22.5%) with grade 3-4 toxicity. Immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 46/84 (54.8%) patients, including 29/46 (63%) with grade 3-4 toxicity. Haemophagocytic lymphohistiocytosis was diagnosed in 15/84 (17.9%) patients. Tocilizumab was used in 73/84 (86.9%) patients, with a median of 2 [1-4] doses. Steroids were given to 55/84 (65.5%) patients, including 21/55 (38.2%) given high-dose pulse therapy. Overall, 23/84 (27.4%) patients had bacterial infections, 3/84 (3.6%) had fungal infections (1 invasive pulmonary aspergillosis and 2 Mucorales), and 2 (2.4%) had cytomegalovirus infection. Vasopressors were required in 23/84 (27.4%), invasive mechanical ventilation in 12/84 (14.3%), and dialysis in 4/84 (4.8%) patients. Four patients died in the ICU (including 2 after ICU readmission, i.e., overall mortality was 4.8% of patients). One year after CAR-T therapy, 41/84 (48.9%) patients were alive and in complete remission, 14/84 (16.7%) were alive and in relapse, and 29/84 (34.5%) had died. These outcomes were similar to those of patients never admitted to the ICU.
CONCLUSION: ICU admission is common after CAR-T therapy and is usually performed to manage specific toxicities. Our experience is encouraging, with low ICU mortality despite a high rate of grade 3-4 toxicities, and half of patients being alive and in complete remission at one year.
参考来源
- Le Cacheux C, Couturier A, Sortais C, et al. Features and outcomes of patients admitted to the ICU for chimeric antigen receptor T cell-related toxicity: a French multicentre cohort. Ann Intensive Care. 2024. PMID: 38291184. doi:10.1186/s13613-024-01247-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。